Principle and Progress of Treating Lymphoma with CD22 as Immunotherapy Target

Abstract

B-cell lymphoma is a type of lymphoid tissue tumour, which is usually caused by clonal proliferation of lymphocytes at different stages of differentiation.  CD22 molecule is ubiquitous in normal B cells and B cell malignant tumours. It is a principal element in the B cell maturation and proliferation, and provides an important functional link to the adjustment of B cell surface and intracellular signaling and cell survival.  Although the function of CD22 remains unclear, blocking the action of CD22 has been proved to inhibit the growth of malignant B cells and CD22 has become an important therapeutic target of B-cell lymphoma.  We will also discuss the strategies for the treatment of B-cell lymphoma targeting CD22, including naked antibodies, bispecific antibodies, antibody-drug conjugate (ADC), antibodies conjugated to radioactive elements, and chimeric antigen receptor-based T-cell (CAR-T) cell immunotherapy.